

# MICROENCAPSULATION OF *MUNTINGIA CALABURA* LEAF KOMBUCHA: EFFECTS ON MICROBIAL VIABILITY, ANTIBACTERIAL ACTIVITY, AND ANTIBIOTIC INTERACTIONS

Marsudi<sup>1</sup> , Sari Rahayu Rahman<sup>2</sup> , Jisril Palayukan<sup>1</sup> , Deka Uli Fahrodi<sup>1</sup> ,  
Nur Saidah Said<sup>1</sup> 

<sup>1</sup> Department of Animal Husbandry, Faculty of Animal Husbandry and Fisheries, Universitas Sulawesi Barat, 91412, Majene, Indonesia

<sup>2</sup> Department of Biology Education, Faculty of Teacher Training and Education, Universitas Sulawesi Barat, 91412, Majene, Indonesia

Link to this article: <https://doi.org/10.11118/actaun.2026.009>

Received: 28. 9. 2025, Accepted: 20. 4. 2026

## Abstract

Kombucha is a fermented beverage rich in organic acids and bioactive compounds with potential antimicrobial properties; however, its microbial stability remains a challenge. This study evaluated the effects of microencapsulation on microbial viability, antibacterial activity, and antibiotic interactions in *Muntingia calabura* leaf kombucha. Microencapsulation was performed using maltodextrin, skim milk, and gum arab, followed by freeze-drying. Microbial viability was assessed using plate counts, antibacterial activity was evaluated by agar diffusion against *Escherichia coli* and *Staphylococcus aureus*, and antibiotic interaction was examined using a modified disc diffusion method. The microencapsulated samples exhibited higher recoverable viable counts upon reconstitution ( $6.27 \times 10^7$  CFU/mL;  $\log 7.79 \pm 0.08$ ) compared with liquid kombucha ( $3.19 \times 10^7$  CFU/mL;  $\log 7.50 \pm 0.04$ ;  $p < 0.05$ ), which is primarily attributed to concentration effects and the protective properties of the encapsulating matrix. Antibacterial activity was generally preserved after microencapsulation, with comparable inhibition zones observed for both test organisms, although minor variations occurred across concentrations. Furthermore, the presence of kombucha influenced the inhibition zones of selected antibiotics, indicating potential modulatory interactions; however, these findings should be interpreted cautiously due to methodological constraints and the use of complex mixtures. In conclusion, microencapsulation can preserve microbial viability and antibacterial activity of *M. calabura* kombucha, supporting its potential application in functional food development. Nevertheless, further studies on microbial characterization, storage stability, and gastrointestinal simulation are required to fully elucidate its functional efficacy.

Keywords: antibacterial activity, kombucha, microencapsulation, *Muntingia calabura*, probiotic

## INTRODUCTION

Kombucha, a traditional fermented beverage, is produced through a symbiotic culture of bacteria and yeast (SCOBY), which converts substrate components into organic acids, polyphenols, and

other bioactive metabolites with well-documented antioxidant and antimicrobial properties (Fraiz *et al.*, 2025; Onsun *et al.*, 2025). Fermentation conditions have been reported to significantly influence the physicochemical and microbiological characteristics of kombucha, including acidity,



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 (CC BY-NC-ND 4.0) International License

metabolite composition, and microbial dynamics (Neffe-Skocińska *et al.*, 2017). In recent years, interest in kombucha has surged, not only as a functional beverage but also as a potential source of probiotics, driven by consumer demand for natural health-promoting products. Furthermore, fermentation substrates, including leaves and fruit extracts beyond *Camellia* species, can significantly influence the bioactive profile and functional properties of the final beverage (Nuryanti, 2022; Zubaidah *et al.*, 2022). Nevertheless, practical applications of kombucha are constrained by two main issues: variability in microbial composition and metabolite profiles, and limited stability and survivability of beneficial microbes and labile bioactives during storage or gastrointestinal passage (Onsun *et al.*, 2025; D'Amico *et al.*, 2025).

Microencapsulation has emerged as a promising strategy to overcome these limitations by entrapping live microbes or bioactive compounds within protective matrices such as polysaccharides, proteins, or lipids, thereby enhancing survival under adverse conditions and enabling controlled release (D'Amico *et al.*, 2025; Budimac *et al.*, 2025). Recent studies indicate that microencapsulation can preserve probiotic viability and bioactivity during processing and storage, and may contribute to improved functional performance under certain conditions (Rode *et al.*, 2025). In parallel, probiotics and their derivatives have gained increasing attention as potential alternatives to antibiotics, particularly in the context of antimicrobial resistance (Ali *et al.*, 2023; Leistikow *et al.*, 2022). However, concerns have also been raised regarding the potential role of microbial products in the dissemination of antimicrobial resistance genes within microbial ecosystems (Tóth *et al.*, 2021; Radovanovic *et al.*, 2023). Despite these advances, most studies have focused on single probiotic strains or simplified food systems, rather than complex fermented beverages such as *Muttingia calabura* leaf kombucha. Consequently, there remains a gap in understanding the combined effects of microencapsulation on microbial viability, antibacterial activity, and antibiotic-related interactions (Nuryanti, 2022; Fraiz *et al.*, 2025).

*Muttingia calabura* leaves are rich in phenolic compounds and flavonoids that may enhance the functional profile of kombucha. Preliminary studies have demonstrated the antimicrobial potential of kombucha produced from *M. calabura* leaves (Nuryanti, 2022). Nevertheless, it remains unclear whether microencapsulation can (i) preserve microbial viability following processing, (ii) maintain antibacterial effectiveness against representative pathogens such as *Escherichia coli* and *Staphylococcus aureus*, and (iii) influence interactions with antibiotics in a manner relevant to the evaluation of kombucha as a functional antimicrobial adjunct. Addressing these questions is

important for the development of stable and effective kombucha-based products. Accordingly, this study evaluates the effects of microencapsulation on the viability, antibacterial activity, and antibiotic interaction profiles of *M. calabura* leaf kombucha using microbial enumeration, agar diffusion assays, and antibiotic interaction testing.

## MATERIALS AND METHODS

### Sample Preparation

Kombucha was prepared using *Muttingia calabura* leaves following standard fermentation procedures (Nuryanti, 2022). The encapsulating matrix consisted of maltodextrin (15%, w/v), skim milk (7.5%, w/v), and gum arab (3%, w/v), prepared based on modified protocols from previous studies. These concentrations were selected to achieve a balance between encapsulation efficiency and solution viscosity. The kombucha was homogenized with the encapsulating agents and subsequently subjected to freeze-drying at -50 °C under a vacuum pressure of approximately 0.1 mbar for 48 hours using a laboratory freeze dryer (Labconco, USA) (Budimac *et al.*, 2025; D'Amico *et al.*, 2025). The resulting microcapsules were stored at 4 °C until further analysis.

### Viability Assessment

Microbial viability was quantified using plate count methods on De Man, Rogosa and Sharpe (MRS) agar (Merck, Germany). Serial dilutions were prepared, and aliquots (100 µL) were spread onto agar plates. Plates were incubated under anaerobic conditions using an anaerobic jar system at 37 °C for 48 hours. Colony counts were expressed as CFU/mL and Log<sub>10</sub> (CFU/mL), calculated from triplicate measurements (D'Amico *et al.*, 2025).

### Antibacterial Activity

Antibacterial activity was evaluated using the disc diffusion method. Test organisms included *Escherichia coli* ATCC 25922 and *Staphylococcus aureus* ATCC 6538. Bacterial suspensions were prepared and adjusted to 0.5 McFarland standard (approximately  $1 \times 10^8$  CFU/mL). Sterile Mueller–Hinton agar (MHA; Merck, Germany) plates were prepared by pouring 15 mL of medium into Petri dishes and allowed to solidify. A sterile cotton swab was immersed in each bacterial suspension and uniformly spread over the entire agar surface to obtain a confluent lawn. Sterile paper discs were impregnated with kombucha samples at concentrations of 1%, 5%, 10%, 15%, and 20%, as well as distilled water (negative control) and amoxicillin 25 µg/disc (positive control), and then placed onto the inoculated agar surface. Each sterile disc was impregnated with 20 µL of sample solution and allowed to dry briefly under sterile conditions prior to placement. All treatments were performed in triplicate. Plates were incubated under aerobic conditions at 37 °C for 24 hours.

Inhibition zones were measured in millimetres using a digital caliper, and the diameter included the disc (Rode *et al.*, 2025).

#### Antibiotic Interaction Assay

The interaction between kombucha samples and antibiotics was evaluated using a modified disc diffusion method based on CLSI guidelines. Antibiotic discs (Oxoid Ltd., UK) included ciprofloxacin (5 µg), colistin (10 µg), amoxicillin (25 µg), streptomycin (10 µg), chloramphenicol (30 µg), tetracycline (30 µg), ampicillin (10 µg), and gentamicin (10 µg). A volume of 50 µL of kombucha sample was applied to the agar surface prior to placement of antibiotic discs to assess potential modulatory effects. Plates were incubated at 37 °C for 24 hours under aerobic conditions. The interpretation of inhibition zones as resistant (R), intermediate (I), or sensitive (S) followed CLSI (2023) guidelines; however, these classifications were used cautiously due to the involvement of complex mixtures rather than pure antibiotics (Onsun *et al.*, 2025).

#### Statistical Analysis

All experiments were conducted in triplicate, and results were expressed as mean ± standard deviation. Statistical analysis was performed using one-way analysis of variance (ANOVA) followed by Tukey's post hoc test to evaluate differences between concentrations and between sample types. A significance level of  $p < 0.05$  was applied.

## RESULTS AND DISCUSSION

#### Viability Assessment

The viability of microorganisms in liquid and microencapsulated *Muntingia calabura* leaf kombucha is presented in Tab. I. The results indicate that the microencapsulated samples showed higher viable counts ( $6.27 \times 10^7$  CFU/mL;  $7.79 \pm 0.08$  log CFU/mL) compared to the liquid form ( $3.19 \times 10^7$  CFU/mL;  $7.50 \pm 0.04$  log CFU/mL), with the difference being statistically significant ( $p < 0.05$ ).

This apparent increase, however, should be interpreted cautiously. The higher counts observed in the microencapsulated samples are most likely associated with a concentration effect resulting from water removal during the freeze-drying process, rather than a genuine increase in microbial cell numbers. Similar observations have been reported in previous studies, where increased

CFU values after drying were attributed to cell concentration rather than microbial proliferation (de Lima *et al.*, 2024; Phan Van *et al.*, 2024). As the liquid kombucha is converted into powder, microbial cells become more densely distributed, which can lead to elevated CFU values upon reconstitution. The comparison between liquid and microencapsulated samples was performed after reconstitution of the powder form; therefore, the observed differences in CFU values primarily reflect concentration effects and recovery efficiency rather than direct equivalence of initial microbial biomass. Thus, the observed difference should be interpreted as a methodological artifact rather than a biological enhancement.

In addition, the encapsulating agents used in this study, namely maltodextrin, skim milk, and gum arab, may have contributed to improved cell survival during processing. These materials are widely recognized for their protective properties, particularly in reducing cellular damage caused by dehydration and osmotic stress (Sbehat *et al.*, 2022; Vivek *et al.*, 2023). The enhanced stability of encapsulated cells under stress conditions has also been associated with the use of protein polysaccharide matrices, which improve resistance to dehydration and environmental stress (Song *et al.*, 2024). Previous studies have also demonstrated that microencapsulation can enhance microbial stability under adverse conditions by forming a protective barrier around the cells (Liu *et al.*, 2023). Therefore, the observed results are better understood as reflecting enhanced preservation and recovery of viable cells, rather than an actual increase in microbial growth. It is also important to note that kombucha represents a complex microbial consortium consisting of bacteria and yeasts (Jayabalan *et al.*, 2014; Villarreal-Soto *et al.*, 2018). In the present study, viability was assessed using MRS agar, which predominantly supports the growth of lactic acid bacteria. Consequently, the results presented here reflect only a portion of the microbial community and do not capture the full diversity of viable microorganisms present in the system.

A further limitation of this study is the absence of standardization based on dry matter or initial biomass when comparing liquid and microencapsulated samples. Future work should consider expressing viability on a dry-weight basis or applying mass balance approaches to enable more accurate biological comparisons.

I: Viability of microorganisms in *Muntingia calabura* leaf kombucha and its microencapsulated form

| Sample                                                    | Viable count (CFU/mL)         | Log <sub>10</sub> (CFU/mL) |
|-----------------------------------------------------------|-------------------------------|----------------------------|
| <i>Muntingia calabura</i> leaf kombucha                   | $(3.19 \pm 0.29) \times 10^7$ | $7.50 \pm 0.04^a$          |
| Microencapsulated <i>Muntingia calabura</i> leaf kombucha | $(6.27 \pm 1.20) \times 10^7$ | $7.79 \pm 0.08^b$          |

Data are presented as mean ± standard deviation (n = 3). Different superscript letters indicate significant differences between samples ( $p < 0.05$ , independent t-test).

### Antibacterial Activity

The antibacterial activity of *Muntingia calabura* leaf kombucha and its microencapsulated form against *Escherichia coli* and *Staphylococcus aureus* is presented in Tab. II. Overall, both samples exhibited measurable antibacterial effects, as indicated by the formation of inhibition zones across all tested concentrations. The inhibition zones generally increased with increasing concentration, suggesting a dose-dependent antibacterial effect. For *E. coli*, the inhibition zones of the liquid kombucha ranged from 5.83 to 14.17 mm, while the microencapsulated form ranged from 6.17 to 13.50 mm. A similar trend was observed for *S. aureus*, where inhibition zones ranged from 5.50 to 13.83 mm for the liquid form and from 5.83 to 13.67 mm for the microencapsulated samples. These results indicate that microencapsulation did not consistently enhance antibacterial activity but was able to maintain comparable inhibitory effects relative to the liquid form.

Data are presented as mean  $\pm$  standard deviation (n = 3). Each sterile disc was impregnated with 20  $\mu$ L

of sample at the indicated concentration. Different superscript letters within the same bacterial group indicate significant differences ( $p < 0.05$ ).

The antibacterial activity observed in this study is likely associated with the presence of organic acids, phenolic compounds, and other bioactive metabolites produced during kombucha fermentation (Jayabalan *et al.*, 2014; Villarreal-Soto *et al.*, 2018). These compounds have been widely reported to inhibit the growth of both Gram-negative and Gram-positive bacteria by disrupting cell membranes and interfering with metabolic processes.

Microencapsulation may contribute to the preservation of these bioactive compounds by providing a protective matrix that reduces degradation during processing (Sbehat *et al.*, 2022; Vivek *et al.*, 2023). However, the results of the present study suggest that such protection did not necessarily translate into increased antibacterial activity, but rather helped retain the functional properties of the kombucha. The slight reduction in antibacterial activity against *E. coli* observed at certain concentrations may be attributed to diffusion limitations of encapsulated bioactive

II: Antibacterial activity of *Muntingia calabura* leaf kombucha and its microencapsulated form at different concentrations (disc diffusion method)

| Bacteria  | Sample                                                    | Concentration (%) | Inhibition zone (mm)<br>Mean $\pm$ SD |
|-----------|-----------------------------------------------------------|-------------------|---------------------------------------|
| E. coli   | <i>Muntingia calabura</i> leaf kombucha                   | 1                 | 5.83 $\pm$ 0.76 <sup>a</sup>          |
|           |                                                           | 5                 | 6.50 $\pm$ 0.50 <sup>a</sup>          |
|           |                                                           | 10                | 6.83 $\pm$ 0.29 <sup>a</sup>          |
|           |                                                           | 15                | 11.17 $\pm$ 0.29 <sup>b</sup>         |
|           |                                                           | 20                | 14.17 $\pm$ 0.29 <sup>c</sup>         |
|           | Microencapsulated <i>Muntingia calabura</i> leaf kombucha | 1                 | 6.17 $\pm$ 0.29 <sup>a</sup>          |
|           |                                                           | 5                 | 7.33 $\pm$ 0.29 <sup>a</sup>          |
|           |                                                           | 10                | 9.17 $\pm$ 0.29 <sup>b</sup>          |
|           |                                                           | 15                | 11.83 $\pm$ 0.76 <sup>c</sup>         |
|           |                                                           | 20                | 13.50 $\pm$ 0.50 <sup>c</sup>         |
|           | Positive control (Amoxicillin 25 $\mu$ g/disc)            | -                 | 20.17 $\pm$ 0.58 <sup>d</sup>         |
|           | Negative control (Distilled water)                        | -                 | 0.00 $\pm$ 0.00 <sup>e</sup>          |
| S. aureus | <i>Muntingia calabura</i> leaf kombucha                   | 1                 | 5.50 $\pm$ 0.87 <sup>a</sup>          |
|           |                                                           | 5                 | 6.17 $\pm$ 0.29 <sup>a</sup>          |
|           |                                                           | 10                | 6.50 $\pm$ 0.29 <sup>a</sup>          |
|           |                                                           | 15                | 11.50 $\pm$ 0.50 <sup>b</sup>         |
|           |                                                           | 20                | 13.83 $\pm$ 0.29 <sup>c</sup>         |
|           | Microencapsulated <i>Muntingia calabura</i> leaf kombucha | 1                 | 5.83 $\pm$ 0.29 <sup>a</sup>          |
|           |                                                           | 5                 | 7.17 $\pm$ 0.29 <sup>a</sup>          |
|           |                                                           | 10                | 9.00 $\pm$ 0.00 <sup>b</sup>          |
|           |                                                           | 15                | 12.17 $\pm$ 0.29 <sup>c</sup>         |
|           |                                                           | 20                | 13.67 $\pm$ 0.58 <sup>c</sup>         |
|           | Positive control (Amoxicillin 25 $\mu$ g/disc)            | -                 | 20.83 $\pm$ 0.29 <sup>d</sup>         |
|           | Negative control (Distilled water)                        | -                 | 0.00 $\pm$ 0.00 <sup>e</sup>          |

Data are presented as mean  $\pm$  standard deviation (n = 3). Each sterile disc was impregnated with 20  $\mu$ L of sample at the indicated concentration. Different superscript letters within the same bacterial group indicate significant differences ( $p < 0.05$ ).

compounds within the agar matrix, which can reduce the apparent inhibition zone despite the presence of active metabolites. It should be noted that the antibacterial activity was evaluated using the disc diffusion method under standardized loading conditions, where equal sample volumes were applied to each disc. Therefore, the observed differences reflect variations in concentration-dependent activity rather than differences in sample volume.

#### **Antibiotic Interaction Assay**

The interaction between *Muntingia calabura* leaf kombucha and selected antibiotics is presented in Tab. III. Variations in inhibition zone diameters

were observed when antibiotics were applied in the presence of kombucha samples, suggesting potential modulatory interactions with antibiotic activity.

However, these observations should be interpreted with caution. The classification of inhibition zones into categories such as sensitive or resistant is based on standardized guidelines developed for pure antibiotics and may not be directly applicable to complex mixtures such as kombucha. Therefore, the results in this study are intended for comparative purposes only and do not represent clinical antibiotic susceptibility. The observed variations may be associated with interactions between bioactive compounds present in kombucha, such as organic acids, phenolics, and

III: *Effect of Muntingia calabura leaf kombucha and its microencapsulated form on antibiotic interactions*

| Sample                                  | Antibiotics                | Concentration (%) | Mean $\pm$ SD (mm) | Interpretation |
|-----------------------------------------|----------------------------|-------------------|--------------------|----------------|
| <i>Muntingia calabura</i> leaf kombucha | Ciprofloxacin 5 $\mu$ g    | 1                 | 5.7 $\pm$ 0.6      | Resistant      |
|                                         |                            | 5                 | 6.3 $\pm$ 0.6      | Resistant      |
|                                         |                            | 10                | 7.3 $\pm$ 0.6      | Resistant      |
|                                         |                            | 15                | 10.0 $\pm$ 1.0     | Resistant      |
|                                         |                            | 20                | 11.7 $\pm$ 0.6     | Intermediate   |
|                                         | Colistin 10 $\mu$ g        | 1                 | 4.3 $\pm$ 0.6      | Resistant      |
|                                         |                            | 5                 | 5.3 $\pm$ 0.6      | Resistant      |
|                                         |                            | 10                | 7.3 $\pm$ 0.6      | Resistant      |
|                                         |                            | 15                | 7.7 $\pm$ 0.6      | Resistant      |
|                                         |                            | 20                | 8.3 $\pm$ 0.6      | Resistant      |
|                                         | Amoxicillin 25 $\mu$ g     | 1                 | 6.7 $\pm$ 0.6      | Resistant      |
|                                         |                            | 5                 | 8.3 $\pm$ 0.6      | Resistant      |
|                                         |                            | 10                | 9.7 $\pm$ 0.6      | Resistant      |
|                                         |                            | 15                | 10.3 $\pm$ 0.6     | Resistant      |
|                                         |                            | 20                | 10.7 $\pm$ 0.6     | Intermediate   |
|                                         | Streptomycin 10 $\mu$ g    | 1                 | 10.3 $\pm$ 0.6     | Intermediate   |
|                                         |                            | 5                 | 11.7 $\pm$ 0.6     | Intermediate   |
|                                         |                            | 10                | 13.3 $\pm$ 0.6     | Sensitive      |
|                                         |                            | 15                | 14.3 $\pm$ 0.6     | Sensitive      |
|                                         |                            | 20                | 15.0 $\pm$ 0.0     | Sensitive      |
|                                         | Chloramphenicol 30 $\mu$ g | 1                 | 12.0 $\pm$ 1.0     | Intermediate   |
|                                         |                            | 5                 | 13.7 $\pm$ 0.6     | Intermediate   |
|                                         |                            | 10                | 14.7 $\pm$ 0.6     | Intermediate   |
|                                         |                            | 15                | 15.7 $\pm$ 0.6     | Sensitive      |
|                                         |                            | 20                | 16.3 $\pm$ 0.6     | Sensitive      |
|                                         | Tetracycline 30 $\mu$ g    | 1                 | 7.0 $\pm$ 0.0      | Resistant      |
|                                         |                            | 5                 | 8.3 $\pm$ 0.6      | Resistant      |
|                                         |                            | 10                | 9.7 $\pm$ 0.6      | Resistant      |
|                                         |                            | 15                | 10.7 $\pm$ 0.6     | Intermediate   |
|                                         |                            | 20                | 11.3 $\pm$ 0.6     | Intermediate   |
|                                         | Ampicillin 10 $\mu$ g      | 1                 | 6.3 $\pm$ 0.6      | Resistant      |
|                                         |                            | 5                 | 7.0 $\pm$ 0.0      | Resistant      |
|                                         |                            | 10                | 8.7 $\pm$ 0.6      | Resistant      |
|                                         |                            | 15                | 9.7 $\pm$ 0.6      | Intermediate   |
|                                         |                            | 20                | 10.3 $\pm$ 0.6     | Intermediate   |

| Sample                                                    | Antibiotics                | Concentration (%) | Mean $\pm$ SD (mm) | Interpretation |
|-----------------------------------------------------------|----------------------------|-------------------|--------------------|----------------|
| <i>Muntingia calabura</i> leaf kombucha                   | Gentamicin 10 $\mu$ g      | 1                 | 12.3 $\pm$ 0.6     | Intermediate   |
|                                                           |                            | 5                 | 13.0 $\pm$ 0.0     | Intermediate   |
|                                                           |                            | 10                | 13.3 $\pm$ 0.6     | Intermediate   |
|                                                           |                            | 15                | 14.7 $\pm$ 0.6     | Sensitive      |
|                                                           |                            | 20                | 15.0 $\pm$ 0.0     | Sensitive      |
|                                                           | Ciprofloxacin 5 $\mu$ g    | 1                 | 5.3 $\pm$ 0.6      | Resistant      |
|                                                           |                            | 5                 | 6.7 $\pm$ 0.6      | Resistant      |
|                                                           |                            | 10                | 8.0 $\pm$ 0.0      | Resistant      |
|                                                           |                            | 15                | 9.7 $\pm$ 0.6      | Resistant      |
|                                                           |                            | 20                | 11.3 $\pm$ 0.6     | Intermediate   |
| Microencapsulated <i>Muntingia calabura</i> leaf kombucha | Colistin 10 $\mu$ g        | 1                 | 4.7 $\pm$ 0.6      | Resistant      |
|                                                           |                            | 5                 | 5.7 $\pm$ 0.6      | Resistant      |
|                                                           |                            | 10                | 7.7 $\pm$ 0.6      | Resistant      |
|                                                           |                            | 15                | 8.3 $\pm$ 0.6      | Resistant      |
|                                                           |                            | 20                | 9.3 $\pm$ 0.6      | Resistant      |
|                                                           | Amoxicillin 25 $\mu$ g     | 1                 | 6.3 $\pm$ 0.6      | Resistant      |
|                                                           |                            | 5                 | 8.7 $\pm$ 0.6      | Resistant      |
|                                                           |                            | 10                | 10.3 $\pm$ 0.6     | Intermediate   |
|                                                           |                            | 15                | 10.7 $\pm$ 0.6     | Intermediate   |
|                                                           |                            | 20                | 11.3 $\pm$ 0.6     | Intermediate   |
|                                                           | Streptomycin 10 $\mu$ g    | 1                 | 10.7 $\pm$ 0.6     | Intermediate   |
|                                                           |                            | 5                 | 12.3 $\pm$ 0.6     | Intermediate   |
|                                                           |                            | 10                | 13.7 $\pm$ 0.6     | Sensitive      |
|                                                           |                            | 15                | 14.7 $\pm$ 0.6     | Sensitive      |
|                                                           |                            | 20                | 15.3 $\pm$ 0.6     | Sensitive      |
|                                                           | Chloramphenicol 30 $\mu$ g | 1                 | 11.7 $\pm$ 0.6     | Intermediate   |
|                                                           |                            | 5                 | 13.3 $\pm$ 0.6     | Intermediate   |
|                                                           |                            | 10                | 15.3 $\pm$ 0.6     | Sensitive      |
|                                                           |                            | 15                | 16.3 $\pm$ 0.6     | Sensitive      |
|                                                           |                            | 20                | 16.7 $\pm$ 0.6     | Sensitive      |
|                                                           | Tetracycline 30 $\mu$ g    | 1                 | 6.7 $\pm$ 0.6      | Resistant      |
|                                                           |                            | 5                 | 8.7 $\pm$ 0.6      | Resistant      |
|                                                           |                            | 10                | 10.3 $\pm$ 0.0     | Intermediate   |
|                                                           |                            | 15                | 11.3 $\pm$ 0.6     | Intermediate   |
|                                                           |                            | 20                | 12.3 $\pm$ 0.6     | Intermediate   |
|                                                           | Ampicillin 10 $\mu$ g      | 1                 | 6.7 $\pm$ 0.6      | Resistant      |
|                                                           |                            | 5                 | 7.7 $\pm$ 0.6      | Resistant      |
|                                                           |                            | 10                | 9.3 $\pm$ 0.6      | Resistant      |
|                                                           |                            | 15                | 10.3 $\pm$ 0.6     | Intermediate   |
|                                                           |                            | 20                | 11.7 $\pm$ 0.6     | Intermediate   |
|                                                           | Gentamicin 10 $\mu$ g      | 1                 | 11.7 $\pm$ 0.6     | Intermediate   |
|                                                           |                            | 5                 | 12.7 $\pm$ 0.6     | Intermediate   |
|                                                           |                            | 10                | 14.3 $\pm$ 0.6     | Sensitive      |
|                                                           |                            | 15                | 15.3 $\pm$ 0.6     | Sensitive      |
|                                                           |                            | 20                | 16.5 $\pm$ 0.6     | Sensitive      |

Data are presented as mean  $\pm$  standard deviation (n = 3). Antibiotic concentrations are expressed as  $\mu$ g/disc. The interpretation (Resistant, Intermediate, Sensitive) was adapted from CLSI guidelines and used for comparative purposes only.

other metabolites and the antibiotics used in this study (Jayabalan *et al.*, 2014; Villarreal-Soto *et al.*, 2018). These compounds may influence bacterial cell permeability or metabolic activity, which could in turn affect the apparent efficacy of antibiotics.

In addition, microencapsulation may play a role in modulating these interactions by influencing the stability and release profile of bioactive compounds (Sbehat *et al.*, 2022; Vivek *et al.*, 2023). However, the results obtained in this study do not allow definitive conclusions regarding synergistic or antagonistic effects, as more specific methods such as checkerboard assays or fractional inhibitory concentration (FIC) analysis would be required. Overall, the findings suggest that kombucha may interact with antibiotics in a manner that affects observed inhibition zones, although further investigation is needed to clarify the underlying mechanisms and clinical relevance.

This study has several limitations that should be considered. In addition, this study did not

differentiate between lactic acid bacteria, acetic acid bacteria, and yeasts present in the kombucha culture, which limits the interpretation of microbial viability and functional properties. Furthermore, storage stability and shelf-life evaluation were not assessed; therefore, the long-term protective effect of the encapsulation process cannot be confirmed under different storage conditions. The comparison between liquid and microencapsulated samples was performed after reconstitution, and thus the observed differences in CFU values primarily reflect concentration effects and recovery efficiency rather than direct equivalence of initial microbial biomass. Additionally, *in vitro* gastrointestinal simulation was not conducted, and the survival of encapsulated microorganisms under digestive conditions remains unclear. Future studies should incorporate detailed microbial characterization, long-term stability assessment, and gastrointestinal simulation to provide a more comprehensive evaluation of encapsulation efficacy.

## CONCLUSION

This study demonstrates that microencapsulation of *Muntingia calabura* leaf kombucha using maltodextrin, skim milk, and gum arab can preserve microbial viability following freeze-drying, as reflected by the recovery of viable counts upon reconstitution. The higher recoverable counts observed in the microencapsulated samples were primarily attributed to concentration effects rather than a true biological enhancement. Both liquid and microencapsulated kombucha exhibited concentration-dependent antibacterial activity against *Escherichia coli* and *Staphylococcus aureus*, with the encapsulated form maintaining comparable inhibitory effects. In addition, the interaction assay indicated that kombucha may influence the observed activity of selected antibiotics; however, these findings should be interpreted cautiously due to methodological limitations and the use of complex mixtures. Overall, microencapsulation represents a promising approach for preserving the functional properties of kombucha. Nevertheless, further studies involving detailed microbial characterization, storage stability, and gastrointestinal simulation are required to fully elucidate its functional efficacy and potential applications.

## Acknowledgements

The authors gratefully acknowledge the Directorate of Research and Community Service for funding support through the Regular Fundamental Research scheme (Contract No. 179/UN55.L1/DT.05.00/2025). Sincere appreciation is also extended to the research team for their valuable collaboration, which contributed to the successful completion of this study.

## REFERENCES

- ALI, M. S., LEE, E. B., HSU, W. H., SUK, K., SAYEM, S. A. J., ULLAH, H. A., LEE, S. J. PARK, S. C. 2023. Probiotics and postbiotics as an alternative to antibiotics: An emphasis on pigs. *Pathogens*. 12(7), 874.
- BUDIMAC, T., PEZO, L., ŠOVLJANSKI, O., CVETKOVIĆ, D., CVANIĆ, T., VUČETIĆ, A. RANITOVIĆ, A. 2025. An Optimal Probiotic Carrier: Multiple Steps Toward Selection and Application in Kombucha. *Fermentation*. 11(5), 256.
- D'AMICO, V., CAVALIERE, M., IVONE, M., LACASSIA, C., CELANO, G., VACCA, M., LA FORGIA, F. M., FONTANA, S., DE ANGELIS, M., DENORA, N. LOPEDOTA, A. A. 2025. Microencapsulation of probiotics for enhanced stability and health benefits in dairy functional foods: a focus on pasta filata cheese. *Pharmaceutics*. 17(2), 185.
- FRAIZ, G. M., BONIFÁCIO, D. B., DE PAULO, R. S., TEIXEIRA, C. M., MARTINO, H. S. D., BARROS, F. A. R. D., MILAGRO, F. I. BRESSAN, J. 2025. Benefits of Kombucha Consumption: A Systematic Review of Clinical Trials Focused on Microbiota and Metabolic Health. *Fermentation*. 11(6), 353.

- JAYABALAN, R., MALBAŠA, R. V., LONČAR, E. S., VITAS, J. S. SATHISHKUMAR, M. 2014. A review on kombucha tea microbiology, composition, fermentation, beneficial effects, toxicity, and tea fungus. *Comprehensive reviews in food science and food safety*. 13(4), 538–550.
- LEISTIKOW, K. R., BEATTIE, R. E. HRISTOVA, K. R. 2022. Probiotics beyond the farm: Benefits, costs, and considerations of using antibiotic alternatives in livestock. *Frontiers in Antibiotics*. 1, 1003912.
- DE LIMA, A. S. L., MAGALHÃES-GUEDES, K. T., MACEDO, J. A. 2024. Efficiency of freeze- and spray-dried microbial preparation as active dried starter culture in kombucha fermentation. *J Sci Food Agric*. 104(2), 674–83.
- LIU, Q., LIN, C., YANG, X., WANG, S., YANG, Y., LIU, Y., XIONG, M., XIE, Y., BAO, Q. YUAN, Y., 2023. Improved viability of probiotics via microencapsulation in whey-protein-isolate-octenyl-succinic-anhydride-starch-complex coacervates. *Molecules*. 28(15), 5732.
- NEFFE-SKOCIŃSKA, K., SIONEK, B., ŚCIBISZ, I. KOŁOŻYN-KRAJEWSKA, D. 2017. Acid contents and the effect of fermentation condition of Kombucha tea beverages on physicochemical, microbiological and sensory properties. *Cyta-journal of food*. 15(4), 601–607.
- NURYANTI, S. 2022. Production of kombucha from *Muntingia calabura* L. leaves and evaluation of its antibacterial activity and total flavonoid content. *Journal of Applied Pharmaceutical Science*. 12(8), 187–192.
- ONSUN, B., TOPRAK, K. SANLIER, N., 2025. Kombucha Tea: A Functional Beverage and All its Aspects. *Current Nutrition Reports*. 14(1), 69.
- PHAN VAN, T., NGUYEN, Q. D., NGUYEN, N. N. DO, A. D. 2024. Efficiency of freeze-and spray-dried microbial preparation as active dried starter culture in kombucha fermentation. *Journal of the Science of Food and Agriculture*. 104(14), 8707–8719.
- RADOVANOVIC, M., KEKIC, D., GAJIC, I., KABIC, J., JOVICEVIC, M., KEKIC, N., OPAVSKI, N. RANIN, L. 2023. Potential influence of antimicrobial resistance gene content in probiotic bacteria on the gut resistome ecosystems. *Frontiers in Nutrition*. 10, 1054555.
- RODE, J., HUTCHINSON, A. N., CHATZOPOULOU, M. S., BLEIEL, S. B., GEBRESENBET, R. F., ANDERSSON, L., PERSSON, J., DAILLÈRE, R., BEITZ, B., ABDALLAH, B. B. TINGÖ, L. 2025. Micro-encapsulation differentially impacts probiotic effects on brain structure and function in an elderly population—A randomised placebo-controlled trial. *Brain, behavior, and immunity*. 106113.
- SBEHAT, M., MAURIELLO, G. ALTAMIMI, M. 2022. Microencapsulation of probiotics for food functionalization: An update on literature reviews. *Microorganisms*. 10(10), 1948.
- SONG, H., LI, R., YANG, L., WANG, S., ZHANG, Y., LI, J., ZHU, D. LIU, H. 2024. Encapsulation of probiotic *Lactocaseibacillus casei* with whey protein isolate/soybean hull polysaccharide enhances cell viability in harsh conditions. *Food Hydrocolloids*. 154, 110126.
- TÓTH, A. G., CSABAI, I., JUDGE, M. F., MARÓTI, G., BECSEI, Á., SPISÁK, S. SOLYMOSI, N., 2021. Mobile antimicrobial resistance genes in probiotics. *Antibiotics*. 10(11), 1287.
- VILLARREAL-SOTO, S. A., BEAUFORT, S., BOUJILA, J., SOUCHARD, J. P. TAILLANDIER, P. 2018. Understanding kombucha tea fermentation: a review. *Journal of food science*. 83(3), 580–588.
- VIVEK, K., MISHRA, S., PRADHAN, R. C., NAGARAJAN, M., KUMAR, P. K., SINGH, S. S., MANVI, D. GOWDA, N. N. 2023. A comprehensive review on microencapsulation of probiotics: technology, carriers and current trends. *Applied Food Research*. 3(1), 100248.
- ZUBAIDAH, E., DEA, E. C. SUJUTI, H. 2022. Physicochemical and microbiological characteristics of kombucha based on various concentration of Javanese turmeric (*Curcuma xanthorrhiza*). *Biocatalysis and Agricultural Biotechnology*. 44, 102467.

#### Contact information

Marsudi: marsudi@unsulbar.ac.id,  <https://orcid.org/0009-0007-4636-7421>

Sari Rahayu Rahman: sarirahayu@unsulbar.ac.id,  <https://orcid.org/0000-0002-7763-0591>

Jisril Palayukan: jisril.palayukan@unsulbar.ac.id,  <https://orcid.org/0000-0003-3126-9195>

Deka Uli Fahrodi: dekaulifahrodi@unsulbar.ac.id,  <https://orcid.org/0009-0004-0086-9504>

Nur Saidah Said: nursaidah@unsulbar.ac.id,  <https://orcid.org/0009-0001-4637-5137>